The PATH panel was designed to cover most targetable mutations and amplifications for lung cancer, colorectal cancer, melanoma, and GIST for first line treatment options, as well in the setting of therapy resistance (e.g. EGFR, ALK and KIT gatekeeper mutations). This evidence concerns the gene ALK and lung carcinoma.